Fruquintinib Combined With PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score: an Open-label, Multi-center, Phase II Clinical Trial
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Fruquintinib (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
Most Recent Events
- 09 Aug 2021 New trial record